How to buy Global Blood Therapeutics stock | $32.78

Global Blood Therapeutics Inc is a biotechnology business based in the US. Global Blood Therapeutics shares (GBT) are listed on the NASDAQ and all prices are listed in US Dollars. Global Blood Therapeutics employs 389 staff and has a trailing 12-month revenue of around 0.00.

Global Blood Therapeutics stock price (NASDAQ: GBT)

Use our graph to track the performance of GBT stocks over time.

Global Blood Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-24.

Latest market close	$32.78
52-week range	$25.11 - $63.03
50-day moving average	$28.21
200-day moving average	$33.46
Wall St. target price	$72.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.30

Buy Global Blood Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Global Blood Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Global Blood Therapeutics price performance over time

Historical closes compared with the close of $32.78 from 2021-10-27

1 week (2021-10-21)	4.53%
1 month (2021-09-28)	23.47%
3 months (2021-07-28)	15.59%
6 months (2021-04-28)	-20.73%

1 year (2020-10-27)	-42.06%
2 years (2019-10-25)	-34.47%
3 years (2018-10-26)	35.93
5 years (2016-10-27)	76.24%

Global Blood Therapeutics financials

Revenue TTM	$164.8 million
Gross profit TTM	$121.8 million
Return on assets TTM	-23.95%
Return on equity TTM	-65.6%
Profit margin	-161.55%
Book value	$5.06
Market capitalisation	$2 billion

TTM: trailing 12 months

Shorting Global Blood Therapeutics shares

There are currently 6.6 million Global Blood Therapeutics shares held short by investors – that's known as Global Blood Therapeutics's "short interest". This figure is 28.9% down from 9.3 million last month.

There are a few different ways that this level of interest in shorting Global Blood Therapeutics shares can be evaluated.

Global Blood Therapeutics's "short interest ratio" (SIR)

Global Blood Therapeutics's "short interest ratio" (SIR) is the quantity of Global Blood Therapeutics shares currently shorted divided by the average quantity of Global Blood Therapeutics shares traded daily (recently around 1.2 million). Global Blood Therapeutics's SIR currently stands at 5.64. In other words for every 100,000 Global Blood Therapeutics shares traded daily on the market, roughly 5640 shares are currently held short.

However Global Blood Therapeutics's short interest can also be evaluated against the total number of Global Blood Therapeutics shares, or, against the total number of tradable Global Blood Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Global Blood Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Global Blood Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1086% of the tradable shares (for every 100,000 tradable Global Blood Therapeutics shares, roughly 109 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Global Blood Therapeutics.

Find out more about how you can short Global Blood Therapeutics stock.

Global Blood Therapeutics share dividends

We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months.

Global Blood Therapeutics share price volatility

Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $25.11 up to $63.03. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 1.0778. This would suggest that Global Blood Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Global Blood Therapeutics overview

Global Blood Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia.

Frequently asked questions

What percentage of Global Blood Therapeutics is owned by insiders or institutions?
Currently 2.484% of Global Blood Therapeutics shares are held by insiders and 107.017% by institutions. How many people work for Global Blood Therapeutics?
Latest data suggests 389 work at Global Blood Therapeutics. When does the fiscal year end for Global Blood Therapeutics?
Global Blood Therapeutics's fiscal year ends in December. Where is Global Blood Therapeutics based?
Global Blood Therapeutics's address is: 181 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Global Blood Therapeutics's ISIN number?
Global Blood Therapeutics's international securities identification number is: US37890U1088 What is Global Blood Therapeutics's CUSIP number?
Global Blood Therapeutics's Committee on Uniform Securities Identification Procedures number is: 37890U108